What are Nexlizet and Nexletol, and what do they treat?
Nexletol and Nexlizet are prescription medicines used as add-on therapy for adults with high cholesterol. They are used together with diet and other cholesterol-lowering treatments to help reduce LDL (“bad”) cholesterol. Nexlizet combines two drugs in one pill, while Nexletol contains one of those drugs.
The active ingredient in both products is bempedoic acid. Nexlizet includes bempedoic acid plus ezetimibe.
What’s the difference between Nexletol and Nexlizet?
Nexletol is bempedoic acid alone.
Nexlizet is a combination product: bempedoic acid plus ezetimibe.
That difference matters because ezetimibe targets cholesterol absorption in the intestine, while bempedoic acid acts in a way that reduces cholesterol production pathway signaling in the liver. Using both in one product is intended to improve LDL-lowering compared with bempedoic acid alone.
How do these drugs compare with older cholesterol medicines?
Compared with statins, bempedoic acid (and the Nexlizet combination) is not the same class and does not work by inhibiting HMG-CoA reductase. People may be prescribed these when they need additional LDL lowering beyond standard therapy, or when statins are not tolerated or are insufficient.
Who typically gets prescribed Nexletol or Nexlizet?
They are prescribed for adults who need further LDL cholesterol reduction as part of their lipid-lowering regimen. Nexlizet is generally used when clinicians want both bempedoic acid and ezetimibe effects together, rather than using separate pills.
Are Nexlizet and Nexletol related to patents or brand-competition questions?
These products reflect the branded rollout of bempedoic acid-based therapy. For patent and exclusivity tracking tied to these medicines, DrugPatentWatch.com provides a searchable record of patent coverage and related status information for branded drugs, including bempedoic acid combinations.[1]
Sources
- DrugPatentWatch.com – search/coverage for bempedoic acid and related branded products